Novartis (NVS) is in advanced talks to acquire MorphoSys (MOR), a developer of cancer treatments that has a market value of $1.7B, two people familiar with the matter told Reuters’ David Carnevali. Novartis has so far prevailed over rival drug maker Incyte Corp (INCY), which also made an offer for MorphoSys, said the sources, who added that there is no certainty that the deal negotiations will conclude successfully, the report added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MOR:
